Methods: We investigate 72 patients who were diagnosed with recurred or metastatic gastric adenocarcinoma in a single center (Chungnam National University Hospital) during March, 2008 to July, 2012. The patient received either FOLFOX or FOLFIRI chemotherapy. this website Results: There were no significant difference between FOLFOX (42 patients) and FOLFIRI (30 patients) group in sex, age, prior surgery, histology and ECOG performance (P > 0.05). FOLFOX group showed response rate 52.4% (CR 21.4% and PR 31%) and

FOLFIRI group showed response rate 46.6% (CR 3.3%, PR 43.3%), but response rate showed no significant difference (P = 0.171). The Time to progression was longer among patients treated with FOLFOX (median, 8.58 month) than among those with FOLFIRI (median, 5.0 month), and this difference statistically

significant (P = 0.032). The overall survival showed no significant difference (P = 0.094), with the oxaliplatin group (28.96 month) LY2157299 datasheet being slightly longer than the irinotecan group (16.48 month). Grade 3/4 Hematologic toxicity (Neutropenia, Anemia and Thrombocytopenia) occurred similarly in both groups. Conclusion: Both combination therapy can be used effectively in recurred or metastatic gastric adenocarcinoma and there were no significant difference between FOLFOX and FOLFIRI in response rate and overall survival. Key Word(s): 1. stomach neoplasm; 2. chemotherapy Presenting Author: KUAN SIANG TAN Additional Authors: TAUFIQUE AHMED Corresponding Author: KUAN SIANG TAN Affiliations: Khoo Teck Puat Hospital Objective: To explore predictive factors associated with diagnosis of lesions, defined as ulcers and carcinomas on endoscopy. Methods: Clinicopathological data of 133 inpatients that underwent endoscopy for investigation of anaemia between October 2013 and Janurary 2014 were analyzed retrospectively. Patients were separated into two groups; patients who had endoscopic and /or histological findings of ulcers and carcinomas constitute the group with lesions and patients without selleck kinase inhibitor lesions

constitute a control group. Patients were scored for each of the associated factors of anaemia including mean corpuscular volume (MCV), ferritin, iron saturation, vitamin B12 levels (B12), folate, presence of end stage renal failure (ESRF) and faecal occult blood (FOB) and a total score was computed for each patient. Univariate analysis was performed to analyze the above individual factors and the total scores for each group of patients. Results: There were 35 patients with lesions and 98 patients without lesions. Univaried analysis showed a high total score is suggestive of a lesion (OR = 1.218, P = 0.024), with low MCV (OR = 2.428, P = 0.021) and positive FOB (OR = 1.826, P = 0.027) individual predictors of a lesion.